The fast-track, single stage Call will cover therapeutics and diagnostics to tackle the outbreak of the novel coronavirus.
IMI plans to launch a Call for proposals on COVID-19, the novel coronavirus that was first reported in China in December 2019 and has since infected over 71 000 people and killed 1 700.
The Call, which will be launched in early March, focuses on the development of:
- therapeutics to address the current COVID-19 outbreak and/or future coronavirus outbreaks
- diagnostics to rapidly and reliably identify people infected with COVID-19.
Preventive vaccines are not included in the scope of this Call.
The World Health Organization has officially declared the COVID-19 outbreak to be a public health emergency of international concern. With this in mind, this Call for proposals is being fast tracked, meaning that the deadline for submitting proposals will be shorter than usual. The Call is also a single-stage Call, meaning EFPIA companies and/or IMI Associated Partners will be part of the applicant consortia from the beginning.
The draft Call text and a Q&A document are available on the Future Topics page of the IMI website.
We will also hold a webinar for potential applicants – registration will open shortly and will be announced in the coming days.
Note: All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.